Pilot Study of Avelumab in Thymic Epithelial Tumors

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

Twenty-seven subjects (15 thymoma, 12 thymic carcinoma) have enrolled in this clinical trial and received treatment with Avelumab. Twenty-four subjects are evaluable for response. Four (17%) partial responses have been observed. Immune-related adverse events (irAEs) of any grade were observed in 12 (48%) patients and included myositis (17%), sicca syndrome (13%), myocarditis and thyroiditis (9% each). irAEs were generally manageable and resolved with appropriate therapy. Low baseline B-cell counts correlated with clinical response and occurrence of some irAEs.